comparemela.com
Home
Live Updates
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ... : comparemela.com
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ...
- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients -
Related Keywords
United States ,
Boston ,
Massachusetts ,
Douglasa Treco ,
Matt Pera ,
Inozyme Pharma ,
Stefan Riley ,
Nasdaq ,
Exchange Commission ,
Drug Administration ,
Facebook ,
Corporate Communications ,
European Medicines Agency ,
Inozyme Pharma Inc ,
Linkedin ,
Twitter ,
Paediatric Committee ,
Planned Pivotal Trial ,
Pediatric Patients ,
Primary Endpoints ,
Radiographic Global Impression ,
Investor Relations ,
Private Securities Litigation Reform Act ,
Annual Report ,
Region ,
comparemela.com © 2020. All Rights Reserved.